Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses notched earlier in the holiday-shortened week.
Shares of companies with a COVID portfolio, including a vaccine, a treatment, or both, reacted with strong moves to the upside in the truncated session on Friday.
